

## Authors' Reply

**Siamak Moradian<sup>1,2</sup>, MD; Marzieh Ebrahimi<sup>3</sup>, PhD; Azade Kanaani<sup>1</sup>, MD; Amir Faramarzi<sup>2</sup>, MD; Sare Safi<sup>1</sup>, PhD**

<sup>1</sup>Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>2</sup>Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>3</sup>Department of Stem Cells, Cell Science Research Center, Royan Institute, Tehran, Iran

**ORCID:**

Siamak Moradian: <https://orcid.org/0000-0002-5328-7565>

*J Ophthalmic Vis Res* 2021; 16 (1): 147–147

Dear Editor,

We would like to thank Dr Arjun Srirampur for his interest in our work. Below please notice our replies:

1. All of our diabetic patients were operated upon due to proliferative diabetic retinopathy (PDR) complications such as non-clearing vitreous hemorrhage and traction retinal detachment but there was no case of rhegmatogenous retinal

detachment; therefore no tamponade was used during surgery.

2. None of our patients had uncontrolled IOP during the short follow-up period (two weeks) after surgery in both groups. The corneal epithelial defect (CED) was improved in all eyes except three; and in those three eyes, lateral tarsorrhaphy and application of a lubricant ointment resulted in healing of the CED less than one month after surgery.

**Correspondence to:**

Siamak Moradian, MD. Department of Ophthalmology, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Pasdaran Ave., Boostan 9 St., Tehran 16666, Iran.  
E-mail: [moradian33195@yahoo.com](mailto:moradian33195@yahoo.com)

**Access this article online**

**Website:** <https://knepublishing.com/index.php/JOVR>

**DOI:** 10.18502/jovr.v16i1.8265

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**How to cite this article:** Moradian S, Ebrahimi M, Kanaani A, Faramarzi A, Safi S. Authors' Reply. *J Ophthalmic Vis Res* 2021;16:147–147.